
Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

While the findings from the most recent CARD study prove promising, it's the toxicity results that have one expert excited.

Published: March 31st 2023 | Updated:

Published: October 6th 2019 | Updated: